Clinical trial · Observational
Detection of Circulating Tumour Cells, Spread Through Air Space in Patients With Lung Cancer
Detection of Circulating Tumour Cells, Spread Through Air Space and Lymph-nodal Micrometastasis in Patients With Lung Cancer Undergoing Surgical Resection With Curative Intent
NCT06833632CI-TRIAL-00086224recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of this study is to evaluate the prognostic impact of the presence of circulating tumour cells Circulating Tumour Cells (CTCs), Spread Through Air Space (STAS) and lymph node micrometastases in patients undergoing radical surgery for non-small cell lung neoplasia
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non-Small-Cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (4)
- measure
- Overall survival (OS)
- timeFrame
- Through study completion, up to 36 months.
- description
- Overall survival (in months) will be assessed for each patient enrolled in the study from the day of surgery to the last follow-up or death whichever comes first
- measure
- Disease-free survival (DFS)
- timeFrame
- Through study completion, up to 36 months.
- description
- DFS (in months) will be assessed for each patient enrolled in the study: the relapse is defined as the first evidence of recurrence of disease on instrumental examinations instrumental examinations performed in the follow-up.
- measure
- Global recurrence rate
- timeFrame
- Through study completion, up to 36 months.
- description
- Percentage of patients with any recurrence
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * obtaining voluntary written informed consent * diagnosis of NSCLC * clinical stage I-IIA cN0 * Candidates for surgical resection Exclusion Criteria: * Pregnancy * Induction therapy for pulmonary neoplasia * Patients who have received systemic treatment for previous cancers in the last three years prior to lung surgery * Any previous surgery for lung cancer * Patients with other active neoplasms * Infiltration of the chest wall
References
Publications (0)
Data not yet available
No reference posted for this study.